SCHEMBL1010858

SCHEMBL1010858

Cc1cc(C)c(N2CCN(c3c(C)cc(C)cc3C)C2C(Cl)(Cl)Cl)c(C)c1

nearest known ligand 0.33

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.33
POLB P06746 2/20 0.33
MAPT P10636 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HTT P42858 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
EBP Q15125 2/20 0.32
DHCR7 Q9UBM7 2/20 0.32
HRH3 Q9Y5N1 3/20 0.31
GAA P10253 1/20 0.30
PKM P14618 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21004217 0.87 NPSR1 (0.33) NPSR1POLBMAPTALDH1A1HTT
SCHEMBL1011157 0.85 POLB (0.35) POLB
SCHEMBL18198916 0.82 ALDH1A1 (0.34) NPSR1POLBMAPTALDH1A1HTT
SCHEMBL23312525 0.81
SCHEMBL1012161 0.78 NPSR1 (0.34) NPSR1POLBMAPTALDH1A1HTT
SCHEMBL1015358 0.78 KDM4E (0.30) ALDH1A1
SCHEMBL11939477 0.77 HRH3 (0.34) NPSR1POLBMAPTALDH1A1HTT
SCHEMBL10029427 0.75 HRH3 (0.37) NPSR1POLBMAPTALDH1A1HTT
SCHEMBL28849788 0.74 HTR2A (0.33)
SCHEMBL14246510 0.74 ALDH1A1 (0.40) NPSR1POLBMAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2280033-B1 DICYCLOPENTADIENE METATHESIS POLYMERISATION CATALYST LTD LIABILITY COMPANY UNITED RES AND DEV CT (RU) 2014-03-12 EP claimed
EP-2280033-A1 DICYCLOPENTADIENE METATHESIS POLYMERISATION CATALYST Limited Liability Company "United Research and Development Centre" (RU) 2011-02-02 EP claimed
EP-1372844-B1 HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR CALIFORNIA INST OF TECHN (US) 2011-01-05 EP claimed
EP-1372844-A4 HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR CALIFORNIA INST OF TECHN (US) 2005-10-12 EP claimed
US-6838489-B2 High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor CYMETECH, LLC (US) 2005-01-04 US claimed
EP-1372844-A1 HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR California Institute of Technology (US) 2004-01-02 EP claimed
WO-2003097562-A2 HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2003-11-27 WO claimed
US-20030144437-A1 High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor STERLING JA, L.C. 2003-07-31 US claimed
US-20030083445-A1 High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor STERLING JA, L.C. 2003-05-01 US claimed
WO-2002076613-A1 HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2002-10-03 WO claimed
US-11779912-B2 Synthesis and characterization of Ru alkylidene complexes UMICORE AG & CO. KG (DE) 2023-10-10 US disclosed
US-11779912-B2 Synthesis and characterization of Ru alkylidene complexes UMICORE AG & CO. KG (DE) 2023-10-10 US disclosed
US-11779912-B2 Synthesis and characterization of Ru alkylidene complexes UMICORE AG & CO. KG (DE) 2023-10-10 US disclosed
CN-114106057-B Synthesis and characterization of Ru alkylene complexes 优美科股份公司及两合公司 2023-06-23 CN disclosed
CN-114106057-A Synthesis and characterization of Ru alkylidene complexes 优美科股份公司及两合公司 2022-03-01 CN disclosed
EP-1372844-A1 HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR California Institute of Technology (US) 2004-01-02 EP disclosed
WO-2003097562-A2 HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2003-11-27 WO disclosed
US-20030144437-A1 High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor STERLING JA, L.C. 2003-07-31 US disclosed
US-20030083445-A1 High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor STERLING JA, L.C. 2003-05-01 US disclosed
WO-2002076613-A1 HIGH ACTIVITY METAL CARBENE METATHESIS CATALYSTS GENERATED USING A THERMALLY ACTIVATED N-HETEROCYCLIC CARBENE PRECURSOR CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2002-10-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144437-A1 High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor NQO1, NIT2, ALOX5 NPSR1 2433/4885POLB 498/4885MAPT 4167/4885
US-11779912-B2 Synthesis and characterization of Ru alkylidene complexes PORCN, ORC3, COASY NPSR1 4665/4885POLB 842/4885MAPT 2030/4885
US-20030083445-A1 High activity metal carbene metathesis catalysts generated using a thermally activated N-heterocyclic carbene precursor NQO1, NIT2, ALOX5 NPSR1 2433/4885POLB 498/4885MAPT 4167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.